Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of PHAT is 22 and suggests 76% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell